Evidence map›Paper›PMID 26286233›Full record

ArticleMucosal immunology2016

IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques.

A M Ortiz, Z A Klase, S R DiNapoli, I Vujkovic-Cvijin, K Carmack, M R Perkins, N Calantone, C L Vinton, N E Riddick, J Gallagher and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Frontiers in microbiomes · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

A M OrtizProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
Z A KlaseProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
S R DiNapoliProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
I Vujkovic-CvijinDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
K CarmackProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
M R PerkinsProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
N CalantoneProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
C L VintonProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
N E RiddickProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
J GallagherProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
N R KlattProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
J M McCuneDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
J D EstesAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
M PaiardiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
J M BrenchleyProgram in Tissue Immunity and Repair and Immunopathogenesis Section, Lab of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USUniversity of California, San Francisco · USEmory National Primate Research CenterLeidos Biomedical Research Inc. (United States)

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Mechanisms of Immune Activation and Disease Progression in Animal ModelsZIAAI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2009 to 2025
$28.2M
Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001029NIH HHS P51 OD010425
6 · The paper itself

Abstract

Increased mortality in antiretroviral (ARV)-treated, HIV-infected individuals has been attributed to persistent immune dysfunction, in part due to abnormalities at the gastrointestinal barrier. In particular, the poor reconstitution of gastrointestinal Th17 cells correlates with residual translocation of dysbiotic, immunostimulatory microflora across a compromised intestinal epithelial barrier. We have previously demonstrated that oral probiotics promote increased intestinal CD4(+) T-cell reconstitution during ARV treatment in a non-human primate model of HIV infection; however, essential mucosal T-cell subsets, such as Th17 cells, had limited recovery. Here, we sought to promote Th17 cell recovery by administering interleukin (IL)-21 to a limited number of ARV-treated, probiotic-supplemented, Simian Immunodeficiency Virus (SIV)-infected pigtailed macaques. We demonstrate that probiotic and IL-21 supplementation of ARVs are associated with enhanced polyfunctional Th17 expansion and reduced markers of microbial translocation and dysbiosis as compared with infected controls receiving ARVs alone. Importantly, treatment resulted in fewer morbidities compared with controls, and was independent of increased immune activation or loss of viral suppression. We propose that combining ARVs with therapeutics aimed at restoring intestinal stasis may significantly improve disease prognosis of ARV-treated, HIV-infected individuals.

Indexed as

AnimalsAnti-Retroviral AgentsBacterial TranslocationCell ProliferationCombined Modality TherapyDysbiosisEmtricitabineGastrointestinal MicrobiomeGastrointestinal TractImmunity, MucosalInterleukin-21InterleukinsMacaca nemestrinaProbioticsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnti-Retroviral AgentsEmtricitabineInterleukin-21InterleukinsTenofovir

Identifiers

PMID26286233
PMCPMC4760912
OpenAlexW1187448213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.